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Abstract. Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease with 
diverse clinical manifestations affecting several organs such as the brain, lungs, kidneys, heart, blood 
vessels, muscles and skin. Oral manifestations might be the first sign and symptoms of SLE. Hence, this 
paper describes a 58-year old lady whom oral lesions were the first manifestation of SLE disease. The oral 
manifestations and management of this patient was discussed.  
1. Introduction 
Systemic lupus erythematosus is chronic autoimmune 
disease in which the body’s own immune system attacks 
its own tissue causes inflammation that leads to cell 
death and tissue destruction (1). However, the etiology 
of this disease remains unknown. The pathogenesis of 
SLE is thought to develop when a T-lymphocyte to an 
antigen-presenting cell (APC) is initiated. The T-cell 
receptor binds to the major histocompatibility complex 
(MHC) portion of the APC, in which lead to cytokine 
release, inflammation, and B-cell stimulation (4).  
SLE is commonly in women and peak onset of age 
is between third and fourth decade of life (2, 3). This 
increased incidence may be attributed to hormones, 
namely oestrogen, as studies have shown women who 
used oral contraceptives or hormonal therapies had an 
increased risk of SLE (5). Oral manifestation of SLE are 
frequently encountered (6) and may include oral 
ulceration, honeycomb plaque, raised keratotic plaque, 
nonspecific erythema, purpura, petechiae and cheilitis 
(7).  
2. Case report  
A 59-year-old Malay lady was admitted to Hospital 
Kuala Lumpur presenting with multiple painful ulcers in 
the oral cavity and on the lips for one week. It was a 
sudden onset. She also complained of burning mouth, 
bleeding gums, and joint pains at hand (wrist), ankle, 
knee and shoulders. Her medical history included 
treatment for valvular heart disease at National Heart 
Institute Malaysia and was previously investigated for 
rheumatoid arthritis. However, patient was discharged 
from rheumatology. 
At initial presentation, she complaint of multiple 
painful oral ulceration in the mouth and lips with 
associated burning mouth, joint pains and causes 
decrease of oral intake. Extraoral examination revealed, 
crusted bleeding ulcerated lesion seen on vermillion 











Fig 1. Crusted bleeding and erosive areas on vermillion border 
of upper and lower lip. 
 
There is no obvious facial swelling, no palpable 
submandibular lymph node and no skin lesion noted on 
examination. Intraorally, ulcers are present at both 
buccal mucosa, tongue and hard palate. The tongue 
revealed whitish coated with ulcers and white patches 
with mild erythema. (Figure 2). Acute ulcerations and 











Fig 2. Erythematous area surrounded by keratoticpatch on the 
dorsum of tongue. 
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Fig 3a. Erythematous patches seen at hard palate. 
 
 
Fig 3b. Well demarcated shallow ulcer with hyperkeratotic 
border and grey base at hard palate. 
 
A complete full blood count (FBC) investigation 
revealed, positive for antinuclear antibody (ANA), anti-
double standard DNA (anti-ds DNA) and ENA SSA. 
Meanwhile, C3 showed 1:10, C4 0.28 and rheumatoid 
factor is within normal ratio. On the basis of clinical and 
examination and investigations, a diagnosis of multiple 
ulceration secondary to systemic lupus erythematosus 
was made. The patient was given IV Hydrocortisone 
100mg in ward and followed by steroid mouthwash used 
at home for a month (Tab Dexamethasone 0.5mg in 
10ml H20). Patient was also prescribed with Gengigel 
mouthwash and gel. Oral hygiene reinforcement and 
dietary advice was also given to the patient for homecare 
management and maintaining oral hygiene. She was 
referred to Rheumatology for the management of SLE. A 
total resolution of mucosal manifestations was achieved 
in one month of topical and systemic steroid therapy. 
3. Discussion 
Systemic lupus erythematosus (SLE) is a serious 
multisystem condition with variety of cutaneous and oral 
manifestations. Oral ulceration is reported to be the most 
common oral manifestation present among SLE patients 
with a prevalence rate ranging between 7 and 41% 
observed to be more severe as the disease (9). The 
commonest site for oral manifestation of SLE are buccal 
mucosa, palate and vermillion border of lips. In the new 
Systemic Lupus International Collaborating Clinics 
Classification Criteria (SLICC) group classification 
criteria, oral ulcers remain as one the clinical features of 
SLE (10). Oral ulcers of SLE presented in various types 
such as palatal erythematous ulcers, aphthous ulcers and 
lupus cheilitis (11). A palatal erythematous ulcer is 
described as painless and single lesion at the hard palate. 
The lupus cheilitis occurs on the buccal lips (especially 
lower lip) with small or diffuse erythematous and 
oedematous or crusty painful ulcers (11). Here in our 
case, patient had multiple ulcers similar presentation of 
ulcers in SLE. 
         In this patient, blood investigation showed positive 
for ANA, anti-ds DNA and ENA SSA. The presence of 
large number of autoantibodies specific to self-antigens 
mainly of nuclear origin (double-stranded DNA 
(dsDNA), Smith antigen and ribonucleoproteins 
(Sm/RNP), anti-Sjogren’s syndrome related antigen A 
and B (SSA/Ro and SSB/La, respectively) is the 
hallmark of the disease. The anti-nuclear antibodies 
(ANAs) are considered markers of diagnosis and 
prognosis of the disease (12). ANA present in 98% of 
patient and most sensitive test. Meanwhile anti-double 
stranded (anti-dsDNA) present in 50-60% of SLE patient 
and highly specific. 
The diagnosis of SLE typically needs four out of 
17 criteria (including at least one clinical criteria and one 
immunologic criteria) or lupus nephritis with presence of 
antinuclear antibody (ANA) or anti-double stranded 
(anti-ds DNA) antibodies based on the Systemic Lupus 
International Collaborating Clinics Classification 
Criteria (SLICC) group classification criteria (10).  
The goals of SLE management are based on 
prevention, reversal of inflammation, maintaining 
conditions of remission and alleviation of symptoms (13). 
Topical corticosteroids (example: 0.1% Triamcinolone 
oral paste) are one of the most frequently used 
medications in SLE. The duration of the steroid usage 
depends on the severity of the symptoms. Local 
treatment oral ulcers such as using Gengigel gel which 
contain hyaluronic acid (HA). The main function of 
Hyaluronic acid includes tissue healing including 
activation and moderation of the inflammatory response, 
promotion of cell proliferation, migration, and 
angiogenesis. A study reported on the efficacy of topical 
0.2% HA on recurrent aphthous ulcer which immediately 
reduced discomfort and also reduced ulcer duration. The 
occurrence of new ulcers was lower when patients are 
treated with Gengigel (13). Steroid mouthwash maybe 
beneficial for multiple oral ulcers in the oral cavity. 
Other treatment such as chlorhexidine mouthwashes help 
to prevent periodontal disease and infection.  
4. Conclusion 
In conclusion, this case report serves to illustrate that 
importance of early diagnosis of oral lesions to recognize 
patients with SLE. Most patients have an episodic 
relapsing and remitting course that may be managed with 
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high-dose steroids during severe flare- ups. Thus, for 
patients with SLE, emphasis is focused on the dental 
team’s continuous reinforcement of good oral hygiene 
and provision of close monitoring  
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